ABBV Stock: $250 Could Be the New Floor After Strong Q3 Results

Pharma‑giant AbbVie Inc. delivered a robust third quarter, surpassing expectations on both revenue and earnings per share — prompting analysts to suggest that the stock’s new support level may be around $250. Total net revenues hit $15.8 billion, up 9.1 % year‑over‑year and ahead of Wall Street’s estimates. The strength was largely driven by blockbuster drugs Skyrizi ($4.7 billion in sales) and RINVOQ ($2.2 billion), offsetting the decline from Humira. AbbVie also raised its full‑year adjusted EPS guidance to $10.61‑$10.65 from the prior $10.38‑$10.58 range. With a 5.5 % dividend increase and an 83 % gross margin on tape, the company signals confidence in its long‑term growth despite near‑term headwinds. Analysts point to the $250 mark as a potential base and highlight upside toward the $280s if momentum continues. #AbbVie #PharmaStocks #DividendGrowth #HealthcareInvesting #SlimScan #GrowthStocks #CANSLIM